Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionAvestar Capital, LLC
Latest Disclosed Ownership3,194 shares
Latest Disclosed Value $ 1,426,441
Avestar Capital, LLC reports 14.28% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Avestar Capital, LLC filed a 13F-HR form disclosing ownership of 3,194 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,426,249 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 2,795 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 14.28% during the quarter. The current value of the position is $1,368,118 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,194 399 14.28 1,426 12.55 0.0916
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,795 -1,077 -27.82 1,267 -16.42 0.0821
2025-11-07 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,872 -239 -5.81 1,517 -17.16 0.0993
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,111 253 6.56 1,830 -2.14 0.1250
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,858 184 5.01 1,870 26.44 0.1624
2025-01-29 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,674 518 16.41 1,480 0.82 0.1257
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,156 104 3.41 1,468 2.59 0.1510
2024-08-08 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,052 148 5.10 1,431 17.89 0.1469
2024-05-10 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,904 694 31.40 1,214 34.93 0.1273
2024-02-12 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,210 237 12.01 899 31.05 0.1019
2023-10-20 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,973 23 1.18 686 0.00 0.0976
2023-08-02 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,950 -1 -0.05 686 11.73 0.1100
2023-04-20 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,951 629 47.58 615 61.15 0.1097
2023-01-20 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,322 -63 -4.55 382 -4.99 0.0691
2022-10-26 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,385 -319 -18.72 401 -16.46 0.1022
2022-07-28 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,704 -4,711 -73.44 480 -71.33 0.1182
2022-04-26 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,415 4,886 319.56 1,674 398.21 0.2672
2022-02-01 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,529 -98 -6.02 336 13.90 0.0411
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,627 128 8.54 295 -2.32 0.0377
2021-08-03 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,499 207 16.02 302 9.42 0.0405
2021-05-03 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,292 92 7.67 276 -2.82 0.0616
2021-02-01 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,200 187 18.46 284 35.24 0.0788
2020-10-29 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,013 220 27.74 210 -8.70 0.0692
2020-07-29 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 793 793 230 0.1016
2019-11-15 2019-09-30 13F/A-1 VERTEX PHARMACEUTCLS COM 92532F100 0 -674 -100.00 0 -100.00
2019-08-06 2019-06-30 13F VERTEX PHARMACEUTCLS COM 92532F100 674 114 20.36 107 24.42 0.0678
2019-05-09 2019-03-31 13F VERTEX PHARMACEUTCLS COM 92532F100 560 -50 -8.20 86 14.67 0.0565
2019-01-25 2018-12-31 13F VERTEX PHARMACEUTCLS COM 92532F100 610 -55 -8.27 75 -29.91 0.0512
2018-10-23 2018-09-30 13F VERTEX PHARMACEUTCLS COM 92532F100 665 38 6.06 107 17.58 0.0619
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTCLS COM 92532F100 627 153 32.28 91 59.65 0.0575
2018-05-10 2018-03-31 13F VERTEX PHARMACEUTCLS COM 92532F100 474 63 15.33 57 26.67 0.0371
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTCLS COM 92532F100 411 411 45 0.0336
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.